Shares of Pliant Therapeutics PLRX have plunged 88.5% in the past three months following recent setbacks in the clinical ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Biomea Fusion (NASDAQ:BMEA – Get Free Report) are both small-cap ...

Michael LaRosa was Jill Biden's press secretary for the first 18 months of Joe Biden's presidency, and in recent weeks he's ...

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested ...

March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating bexotegrast as an IPF treatment.

Pliant is committed to the development of its other clinical and pipeline assets including PLN-101095 in oncology. The Company is currently enrolling the fourth of five planned dose cohorts in a ...

Pliant Therapeutics, Inc.’s PLRX share price has surged by 10.39%, which has investors questioning if this is right time to ...

Pliant Technologies’ CrewCom CB2 Professional Wireless Intercom system “is a full-duplex, install-friendly and feature-packed solution for small to mid-level applications requiring a reliable, great ...

Pliant Therapeutics (PLRX) announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement to ...